Alzheimer’s is a scientific failure. It's an area of research suited to a public private partnership because it offers companies a chance to pool the lessons they've learned, mistakes they've made, and data they've compiled from years of unsuccessful attempts to develop treatments. The Alzheimer's research we fund is looking at the underlying biology rather than going after late-stage cures. We know now that there has been too much focus on the build-up of beta-amyloid in the brain, but beta-amyloid is the end-point. What led to it?